Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854499 · ClinicalTrials.gov registry record · Phase 2
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
NCT04854499: Clinical Trial Phase 2 study, sponsored by Gilead Sciences.
NCT04854499 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 193 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04854499, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
Study Summary
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
Primary Outcome
A DLT was defined as any Grade 3 or higher hematologic toxicity or Grade 3 or higher nonhematologic toxicity that had worsened in severity from pretreatment baseline during the DLT assessment period and, in the opinion of the investigator, the AE was related to magrolimab and the relationship of the AE with the combination partner regimen can be ruled out.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG 5-FU
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2024-10-02 |
| Phase | Phase 2 |
Why NCT04854499 stopped before completion
NCT04854499 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04854499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04854499 about?
NCT04854499 is a clinical study titled "Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma". The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT04854499?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2021-09-07. Estimated completion is 2024-10-02.
What interventions are being tested in trial NCT04854499?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Cisplatin (DRUG), 5-FU (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT04854499?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04854499's enrollment target sits among peer trials
193 352nd of 2000 higher than 1,649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI